Incidence and Immunologic Analysis of Coronavirus Disease (COVID-19) in Hemodialysis Patients: A Single-Center Experience

Arslan, Hande; Muşabak, Uğur; Soy, Ebru H. Ayvazoglu; Azap, Özlem Kurt; Sayın, Burak; Akçay, Şule; Haberal, Kemal Murat; Akdur, Aydıncan; Yıldırım, Sedat; Haberal, Mehmet

doi:10.6002/ect.2020.0194

Cited by 27 publications

(30 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Following a thorough assessment, 58 articles with 13452 patients were included for quantitative synthesis and further investigation (Tables 1 and 2). Most COVID-19 studies were performed in Asia (68%, n ¼ 21) [6,[26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45], followed by Europe (19%, n ¼ 6) [46][47][48][49][50][51] and North America (13%, n ¼ 4) [52][53][54][55]. Most SARS studies were performed in Asia (88%, n ¼ 7) [5,[56][57][58][59][60][61] except for one study from Canada [62], and almost all the MERS studies were performed in Saudi Arabia (95%, n ¼ 18) [3,[63][64][65][66][67][68][69]…”

Section: Search Results and Study Selectionmentioning

confidence: 99%

“…The incidence of COVID-19 was 8.0% (nine studies [30,38,42,44,[46][47][48][49][50], 95% CI: 4.7%-12.0%) in hemodialysis patients with a mortality rate of 25.7% (nine studies [30,38,42,44,46,[49][50][51]53], 95% CI: 21.3%-30.3%). The incidence of SARS was 1.7% (95% CI: 0.9%-3.0%) based on a single study [61] with a mortality rate of 25.0% (95% CI: 5.5%-57.2%).…”

Section: Patients On Chronic Hemodialysis and The Occurrence Of Coronmentioning

confidence: 99%

See 1 more Smart Citation

Coronavirus-associated kidney outcomes in COVID-19, SARS, and MERS: a meta-analysis and systematic review

Zhou

Xue

et al. 2020

Renal Failure

View full text Add to dashboard Cite

Objectives: A meta-analysis and systematic review was conducted on kidney-related outcomes of three recent pandemics: SARS, MERS, and COVID-19, which were associated with potentially fatal acute respiratory distress syndrome (ARDS). Methods: A search of all published studies until 16 June 2020 was performed. The incidence/ prevalence and mortality risk of acute and chronic renal events were evaluated, virus prevalence, and mortality in preexisting hemodialysis patients was investigated. Results: A total of 58 eligible studies involving 13452 hospitalized patients with three types of coronavirus infection were included. The reported incidence of new-onset acute kidney injury (AKI) was 12.5% (95% CI: 7.6%-18.3%). AKI significantly increased the mortality risk (OR ¼ 5.75, 95% CI 3.75-8.77, p < 0.00001) in patients with coronavirus infection. The overall rate of urgentstart kidney replacement therapy (urgent-start KRT) use was 8.9% (95% CI: 5.0%-13.8%) and those who received urgent-start KRT had a higher risk of mortality (OR ¼ 3.43, 95% CI 2.02-5.85, p < 0.00001). Patients with known chronic kidney disease (CKD) had a higher mortality than those without CKD (OR ¼ 1.97, 95% CI 1.56-2.49, p < 0.00001). The incidence of coronavirus infection was 7.7% (95% CI: 4.9%-11.1%) in prevalent hemodialysis patients with an overall mortality rate of 26.2% (95% CI: 20.6%-32.6%). Conclusions: Primary kidney involvement is common with coronavirus infection and is associated with significantly increased mortality. The recognition of AKI, CKD, and urgent-start KRT as major risk factors for mortality in coronavirus-infected patients are important steps in reducing future mortality and long-term morbidity in hospitalized patients with coronavirus infection.

show abstract

Section: Search Results and Study Selectionmentioning

confidence: 99%

Section: Patients On Chronic Hemodialysis and The Occurrence Of Coronmentioning

confidence: 99%

Coronavirus-associated kidney outcomes in COVID-19, SARS, and MERS: a meta-analysis and systematic review

Zhou

Xue

et al. 2020

Renal Failure

View full text Add to dashboard Cite

show abstract

“…All 34 included studies were published in 2020, of which 15 studies reported prevalence outcomes[18-32] and 31 studies reported death outcomes[7, 18, 21-24, 26-50]. There were 17 cohort studies[7, 19, 20, 23-25, 27, 31, 33, 35, 40, 42, 44-46, 49, 50], 12 case series[21, 30, 34, 36-39, 41, 43, 47, 48], and five cross-sectional studies[22, 26, 28, 29, 32]. The number of samples per study ranged from 3 to 7,154 with a total of 1,944 COVID-19 confirmed cases in 21,873 ESRD patients with RRT from 12 countries in four WHO regions which nine countries were high-income countries and three were upper-middle-income countries according to the World Bank classification[51].…”

Section: Resultsmentioning

confidence: 99%

“…Female patients in each study were ranged from 0 to 57%. There were 20 studies on ESRD patients with kidney transplantation (KT) only[21, 23, 24, 26, 28, 30, 34-39, 41, 43, 45-50], ten studies with hemodialysis (HD) only[18-20, 22, 25, 27, 29, 32, 33, 40], four studies with more than one RRT modalities[7, 31, 42, 44], and no studies with peritoneal dialysis (PD) only (Table1).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Covid-19 in end-stage renal disease patients with renal replacement therapies: a systematic review and meta-analysis

Nopsopon

Kittrakulrat

Takkavatakarn

et al. 2021

Preprint

View full text Add to dashboard Cite

IntroductionThe novel coronavirus (COVID-19), caused by SARS-CoV-2, showed various prevalence and case-fatality rates (CFR) among patients with different pre-existing chronic conditions. End-stage renal disease (ESRD) patients with renal replacement therapy (RRT) might have a higher prevalence and CFR due to reduced immune function from uremia and kidney tropism of SARS-CoV-2, but there was no systematic study on the infection and mortality of the SARS-CoV-2 infection in ESRD patients who are on RRT.MethodsWe searched five electronic databases and performed a systematic review and meta-analysis up to June 30, 2020, to evaluate the prevalence and case fatality rate (CFR) of the COVID-19 infection among ESRD patients with RRT. The global COVID-19 data were retrieved from the international database on June 30, 2020, for estimating the prevalence and CFR of the general population as referencing points.ResultsOf 3,272 potential studies, 34 were eligible studies consisted of 1,944 COVID-19 confirmed cases in 21,873 ESRD patients with RRT from 12 countries in four WHO regions. The overall pooled prevalence in ESRD patients with RRT was 3.10% [95% confidence interval (CI) 1.25–5.72] which was higher than referencing 0.14% global average prevalence. The overall estimated CFR of COVID-19 in ESRD patients with RRT was 18.06% (95%CI 14.09– 22.32) which was higher than the global average at 4.98%.ConclusionsThis meta-analysis suggested high COVID-19 prevalence and CFR in ESRD patients with RRT. ESRD patients with RRT should have their specific protocol of COVID-19 prevention and treatment to mitigate excess cases and deaths.Author summaryChronic kidney disease (CKD) was associated with increasing severity and mortality of COVID-19. End-stage renal disease (ESRD) patients were at the terminal stage of CKD and had reduced immune function due to uremia. Additionally, ESRD patients with kidney transplantation had a diminished immune system from immunosuppressive agents. Kidneys might be the secondary target of SARS-CoV-2 after the respiratory tract regardless of the previous history of kidney disease, preferably the glomerulus, which was associated with the richness of some specific protein-coding genes in the kidney. The overall pooled prevalence in ESRD patients with renal replacement therapy was approximately 22 times of the referencing global average prevalence. The overall estimated case fatality rate of COVID-19 in ESRD patients with renal replacement therapy was approximately 3.6 times the global average. ESRD patients with renal replacement therapy had high COVID-19 prevalence and case fatality rate. We suggested that ESRD patients with renal replacement therapy should have their specific protocol of COVID-19 prevention and treatment to mitigate excess cases and deaths.

show abstract

A Recipient and Donor Both Have COVID-19 Disease. Should We Perform a Liver Transplant?

Tunçer

Akbulut

Başkıran

et al. 2021

J Gastrointest Canc

View full text Add to dashboard Cite

Coronavirus 2019 (COVID-19) is a new infectious disease that continues to spread globally. There is growing concern about donor-induced transmission of Coronavirus 2 (SARS ‐CoV‐2). For liver transplantation, the COVID-19 PCR test is routine, in addition to epidemiological history and clinical and radiological examination 24–48 h before surgery. One of the liver transplant candidates was found to be infected with COVID-19, as well as the planned donor candidate. Since COVID-19 will be a high-risk operation for both the recipient and the donor, the operation was postponed by giving medical treatment. After the treatment and quarantine process was over, the patient and the donor then had a negative COVID-19 PCR test and the patient received a living donor liver transplant. We present a case of donor and recipient who initially both tested positive for COVID-19. This liver transplantation scenario has not previously been reported in the literature.

show abstract

Incidence and Immunologic Analysis of Coronavirus Disease (COVID-19) in Hemodialysis Patients: A Single-Center Experience

Cited by 27 publications

References 15 publications

Coronavirus-associated kidney outcomes in COVID-19, SARS, and MERS: a meta-analysis and systematic review

Coronavirus-associated kidney outcomes in COVID-19, SARS, and MERS: a meta-analysis and systematic review

Covid-19 in end-stage renal disease patients with renal replacement therapies: a systematic review and meta-analysis

A Recipient and Donor Both Have COVID-19 Disease. Should We Perform a Liver Transplant?

Contact Info

Product

Resources

About